Bli medlem
Bli medlem

Du är här


Novartis International AG: Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report

Novartis International AG / Novartis highlights progress towards access and
environmental goals in 2016Corporate Responsibility Performance Report .
Processed and transmitted by Nasdaq Corporate Solutions.The issuer is solely
responsible for the content of this announcement.
* Novartis Access-to-medicine programs reached approximately 52 million
patients, including first-year deliveries through the innovative Novartis
Access program
* Novartis improved position in key sustainability rankings, including recent
Corporate Knights' "Global 100 Most Sustainable Corporations in the World"
* 2016 report highlights work towards the United Nations Sustainable
Development Goals and shares trends and challenges within the healthcare

Basel, January 26, 2017
- Novartis published its Corporate Responsibility (CR) Performance Report for
the fourth consecutive year, highlighting progress on access and
environmental goals in 2016. Building on the company's long history of
corporate responsibility and transparent reporting, the 2016 report provides
even more context on the company's CR performance across five key areas:
Access, Ethics, Research&Development, People and Environment. The report
also captures perspectives from external stakeholders on trends and
challenges within the healthcare industry and presents the essential
contributions Novartis makes to the United Nations Sustainable Development

"I'm proud of the progress we've made in aligning our corporate responsibility
and sustainability goals with our business strategy" said Joseph Jimenez, CEO
of Novartis. "Looking to the future, I am eager to work with our teams to
continue embedding corporate responsibility into our ongoing business and
every facet of our work."

Novartis provided medicine to approximately 52 million patients through access
programs in 2016, as well as health education, infrastructure development and
other programs to another 17 million people worldwide. One year since
launch, Novartis Access delivered more than 120,000 treatments for chronic
diseases to Kenya, Lebanon and Ethiopia, each providing a one-month supply of
medicine. The Novartis Access 2016 one-year report, also released today,
captures updates on progress and key learnings.

The Novartis Malaria Initiative achieved another milestone in 2016, with more
than 800 million treatments delivered without profit to malaria-endemic
countries since 2001. At the same time, Novartis launched SMS for Life 2.0
in Kaduna State, Nigeria. The program is an enhanced version of the
award-winning SMS for Life program and uses smartphones and tablet computers
to enable local healthcare workers to manage stock levels of treatments and
receive training. The next-generation antimalarial, KAF156, is also entering
Phase IIb clinical development.

Novartis also took steps toward achieving its Vision 2030 on Environmental
Sustainability and 2020 targets. Overall net greenhouse gas emissions reduced
by 18.7% versus 2010, with an additional net reduction of 10,000 tons through
energy projects in 2016. Development has also begun on an approach to
capture, measure and value the external economic, environmental and social
impacts created by the company's activities.

"Corporate responsibility is a core part of our business strategy," said
Juergen Brokatzky-Geiger, Global Head of Corporate Responsibility. "It drives
our ability to successfully pioneer new business approaches, create scalable
solutions to global healthcare challenges, and partner with organizations
that share our mission of improving and extending people's lives."

Testimony to the progress made, Novartis improved its standing in several key
sustainability rankings. In the 2016 Access to Medicine Index, Novartis
ranked third, up from fourth in 2014 and seventh in 2012. Novartis also
received an A- rating and recognition among category leaders in healthcare in
the 2016 CDP Climate Score. Most recently, in Corporate Knights' 2017 Global
100 Most Sustainable Corporations in the World ranking, the company
significantly improved its standing, moving up 30 ranks from last year to
68th. Novartis was also recognized in Newsweek's Green Rankings and the Dow
Jones Sustainability World Index, as well as in Fortune's 2016 "World's Most
Admired Companies" list.

In 2016, the CR Performance report is again structured in accordance with the
Global Reporting Initiative's (GRI) G4 guidelines, with disclosure at
"comprehensive" level. Novartis has a strong history of CR activities, and
transparent reporting is a central part of its commitment to corporate
responsibility. Novartis has publicly reported on performance in this area
since 2000 through its Annual Report and several online and printed

Download the Novartis Corporate Responsibility Performance Report 2016

Download the Novartis Access 2016 one-year report

Download the Corporate Responsibility section of the Novartis Annual Report

Find out more about our corporate responsibility activities online at:


This press release contains expressed or implied forward-looking statements,
including statements that can be identified by terminology such as
"progress," "building," "goals," "strategy," "looking to the future,"
"eager," "continue," "launch," "launched," "next-generation," "targets,"
"development has also begun," "approach," "mission," "commitment," or similar
expressions. Such forward-looking statements reflect the current views of the
Group regarding future events, and involve known and unknown risks,
uncertainties and other factors that may cause actual results to be
materially different from any future results expressed or implied by such
statements. These expectations could be affected by, among other things,
risks and factors referred to in the Risk Factors section of Novartis AG's
current Form 20-F on file with the US Securities and Exchange Commission.
Novartis is providing the information in this press release as of this date
and does not undertake any obligation to update it in the future.

About Novartis

Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland,
Novartis offers a diversified portfolio to best meet these needs: innovative
medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the
only global company with leading positions in these areas. In 2016, the Group
achieved net sales of USD 48.5 billion, while R&D throughout the Group
amounted to approximately USD 9.0 billion (USD 8.4 billion excluding
impairment and amortization charges). Novartis Group companies employ
approximately 118,000 full-time-equivalent associates. Novartis products are
sold in approximately 155 countries around the world. For more information,
please visit

Novartis is on Twitter. Sign up to follow @Novartis

For Novartis multimedia content, please

For questions about the site or required registration, please

# # #

Novartis Media Relations

Central media line: +41 61 324 2200

| Eric Althoff |
|Novartis Global Media Relations |
|+41 61 324 7999 (direct) |
|+41 79 593 4202 (mobile) |
| |
Novartis Investor Relations

Central investor relations line: +41 61 324 7944

| Central North America |
| Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448 |
| Pierre-Michel Bringer +41 61 324 1065 Sloan Pavsner +1 212 830 2417 |
| Thomas Hungerbuehler +41 61 324 8425 |
| Isabella Zinck +41 61 324 7188 |

Media release (PDF)

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.